Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Mavoglurant in Adolescent Fragile X Syndrome
NCT01433354Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Started Nov 2011; status: terminated.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01433354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01433354.